PrimeRFP SCOUT · Federal Contract Recompete Brief

75N91025C00051SBIR PHASE II - enhanced overall — Novomedix LLC

Novomedix LLC holds $3.0M across 2 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 16 offers. Set-aside status: Small business. Recompete timing centers on the Sep 14, 2027 PoP end — agencies typically plan 12–18 months ahead.

Nih Nci

Awarding office

Novomedix LLC

Recipient

Sep 14, 2027

PoP end

$3M

Obligated

$3M

Potential

541715

NAICS

AN12

PSC

Small business

Set-aside

16 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Small business

Contract number75N91025C00051

AgencyNih Nci

Awarding officeNih Nci

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentNovomedix LLC

CAGE4C2X1

UEIXQYMHKGDMU75

NAICS541715

PSCAN12

Place of performanceSAN DIEGO CA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition After Exclusion Of Sources

Related solicitation75N91024R00019

PoP startSep 15, 2025

PoP end (current)Sep 14, 2027

Obligated$3M

Current value$3M

Potential value$3M

SBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE is a federal Small business award for Nih Nci held by Novomedix LLC. Estimated value $3M ($3M obligated). Current period of performance ends Sep 14, 2027. Last award drew 16 bidders. Place of performance: SAN DIEGO CA. Related solicitation 75N91024R00019.

SBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE

Recompete timing

Public

● Expiring in 352 days

Current PoP ends Sep 14, 2027 (352 days remaining). Agencies typically plan 12–18 months ahead — at 11.6 months out, that window is already open. The buying decision is likely already in motion.

Bonuses end Sept 30

Want the durability read on 75N91025C00051? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Novomedix LLC — $3.0M obligated across 2 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$3.0M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N91025C00051?

75N91025C00051 (SBIR PHASE II - enhanced overall) is a Nih Nci award with a potential value of $3M, currently held by Novomedix LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N91025C00051?

Nih Nci awarded 75N91025C00051 to Novomedix LLC (potential $3M).

Who is the incumbent on 75N91025C00051?

Novomedix LLC is the incumbent with $3.0M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Sep 14, 2027.

When does Novomedix LLC’s 75N91025C00051 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 14, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75N91025C00051? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 2, 2026 · refreshed monthlyLatest procurement action Sep 30, 2025